Amanda M. Dudek

Employment

• University of Iowa Assistant Professor and Microbiology Endowed Scholar
  2025 - Present
• Stanford Medicine Instructor
  2023 - 2025
• Stanford University Post-doctoral Fellow
  2019 - 2023
• Colorado State University Undergraduate Laboratory Assistant
  2010 - 2012

Education

• Harvard University Ph.D./Virology
  2012 - 2019
• Colorado State University B.S./Microbiology
  2007 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Engineering hematopoietic stem and progenitor cells to generate red blood cells as viral traps against HIV-1
  Molecular Therapy Advances 2026 DOI: 10.1016/j.omta.2026.201799
  +Save
• It takes two: A two-component system to visualize single-molecule HIV-1 infection in vivo
  Molecular Therapy Advances 2026 DOI: 10.1016/j.omta.2026.201758
  +Save
• Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies
  Nature Communications 2025 DOI: 10.1038/s41467-025-58371-8
  +Save
• A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection
  Cell Stem Cell 2024 DOI: 10.1016/j.stem.2024.03.002
  +Save
• Combining Cell-Intrinsic and -Extrinsic Resistance to HIV-1 By Engineering Hematopoietic Stem Cells for CCR5 Knockout and B Cell Secretion of Therapeutic Antibodies
  2024 DOI: 10.1101/2024.03.08.583956
  +Save
• Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells.
  Nature communications 2024 DOI: 10.1038/s41467-023-43413-w
  +Save
• High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition.
  Nature biotechnology 2023 DOI: 10.1038/s41587-023-01888-4
  +Save
• Answered and Unanswered Questions in Early-Stage Viral Vector Transduction Biology and Innate Primary Cell Toxicity for Ex-Vivo Gene Editing.
  Frontiers in immunology 2021 DOI: 10.3389/fimmu.2021.660302
  +Save
• Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus.
  Molecular therapy : the journal of the American Society of Gene Therapy 2021 DOI: 10.1016/j.ymthe.2021.03.023
  +Save
• GPR108 Is a Highly Conserved AAV Entry Factor.
  Molecular therapy : the journal of the American Society of Gene Therapy 2019 DOI: 10.1016/j.ymthe.2019.11.005
  +Save